Evaluation of human pancreatic RNase as effector molecule in a therapeutic antibody platform.
about
Endosomal escape efficiency of fusogenic B18 and B55 peptides fused with anti-EGFR single chain Fv as estimated by nuclear translocation.Addressing the Immunogenicity of the Cargo and of the Targeting Antibodies with a Focus on Demmunized Bacterial Toxins and on Antibody-Targeted Human Effector Proteins.Updates in the Development of ImmunoRNases for the Selective Killing of Tumor Cells.
P2860
Evaluation of human pancreatic RNase as effector molecule in a therapeutic antibody platform.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 15 January 2014
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Evaluation of human pancreatic ...... therapeutic antibody platform.
@en
Evaluation of human pancreatic ...... therapeutic antibody platform.
@nl
type
label
Evaluation of human pancreatic ...... therapeutic antibody platform.
@en
Evaluation of human pancreatic ...... therapeutic antibody platform.
@nl
prefLabel
Evaluation of human pancreatic ...... therapeutic antibody platform.
@en
Evaluation of human pancreatic ...... therapeutic antibody platform.
@nl
P2093
P2860
P356
P1476
Evaluation of human pancreatic ...... therapeutic antibody platform.
@en
P2093
André Frenzel
Axel Harrenga
Beate Müller-Tiemann
Beatrix Stelte-Ludwig
Jörg Willuda
Lars Linden
Mark Trautwein
Thomas Schirrmann
P2860
P304
P356
10.4161/MABS.27830
P50
P577
2014-01-15T00:00:00Z